Combating Susceptibility to Drug ResistanceLessons from HIV-1 Protease
نویسندگان
چکیده
منابع مشابه
HIV-1 protease: mechanism and drug discovery.
It has now been two decades since acquired immunodeficiency syndrome (AIDS) was first reported by the US Center for Diseases Control (CDC). A few years later, it was found that a retrovirus called human immunodeficiency virus (HIV) is the causative agent in AIDS. In a short time, AIDS increased to epidemic proportions throughout the world, affecting more than 40 million people today and killing...
متن کاملHIV-1 Protease: Structural Perspectives on Drug Resistance
Antiviral inhibitors of HIV-1 protease are a notable success of structure-based drug design and have dramatically improved AIDS therapy. Analysis of the structures and activities of drug resistant protease variants has revealed novel molecular mechanisms of drug resistance and guided the design of tight-binding inhibitors for resistant variants. The plethora of structures reveals distinct molec...
متن کاملMolecular Basis for Drug Resistance in HIV-1 Protease
HIV-1 protease is one of the major antiviral targets in the treatment of patients infected with HIV-1. The nine FDA approved HIV-1 protease inhibitors were developed with extensive use of structure-based drug design, thus the atomic details of how the inhibitors bind are well characterized. From this structural understanding the molecular basis for drug resistance in HIV-1 protease can be eluci...
متن کاملSparse Representation for HIV-1 Protease Drug Resistance Prediction
HIV rapidly evolves drug resistance in response to antiviral drugs used in AIDS therapy. Estimating the specific resistance of a given strain of HIV to individual drugs from sequence data has important benefits for both the therapy of individual patients and the development of novel drugs. We have developed an accurate classification method based on the sparse representation theory, and demonst...
متن کاملHIV-1 protease inhibitors.
Treatment of human immunodeficiency virus type 1 (HIV-1) infection with regimens that include protease inhibitors (PIs) has contributed to marked improvements in HIV-related disease progression and mortality. Five PIs are approved by the US Food and Drug Administration and have potent activity in vitro. PIs with 2 nucleoside analogue reverse transcriptase inhibitors have demonstrated prolonged ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Chemistry & Biology
سال: 2004
ISSN: 1074-5521
DOI: 10.1016/s1074-5521(04)00243-1